Candriam SCA
MRNA icon

Candriam SCA’s Moderna MRNA Stock Holding History

Candriam SCA’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$74.4M Buy
384,828
+75,632
+24% +$8.15M 0.33% 64
2026
Q2 		$21.6M Buy
309,196
+78,372
+34% +$4.05M 0.1% 193
2026
Q1 		$11.7M Buy
230,824
+1,826
+0.8% +$85.2K 0.06% 254
2025
Q4 		$6.75M Buy
228,998
+11,394
+5% +$310K 0.03% 332
2025
Q3 		$5.62M Sell
217,604
-3,382
-2% -$94.3K 0.03% 354
2025
Q2 		$6.1M Sell
220,986
-60,960
-22% -$1.61M 0.04% 321
2025
Q1 		$7.99M Sell
281,946
-330,916
-54% -$11.7M 0.05% 265
2024
Q4 		$25.5M Sell
612,862
-14,804
-2% -$708K 0.15% 142
2024
Q3 		$41.9M Buy
627,666
+145,614
+30% +$13.4M 0.24% 89
2024
Q2 		$57.2M Buy
482,052
+40,007
+9% +$5.06M 0.35% 63
2024
Q1 		$47.1M Buy
442,045
+79,001
+22% +$7.96M 0.3% 74
2023
Q4 		$36.1M Sell
363,044
-79,316
-18% -$6.67M 0.25% 92
2023
Q3 		$45.7M Buy
442,360
+92,221
+26% +$10.3M 0.32% 68
2023
Q2 		$42.5M Sell
350,139
-58,055
-14% -$7.74M 0.31% 76
2023
Q1 		$57.7M Sell
408,194
-11,933
-3% -$1.97M 0.4% 58
2022
Q4 		$75.5M Buy
420,127
+174,228
+71% +$28.5M 0.51% 38
2022
Q3 		$29.1M Buy
245,899
+110,425
+82% +$16.8M 0.2% 109
2022
Q2 		$19.4M Buy
135,474
+5,224
+4% +$747K 0.16% 145
2022
Q1 		$22.4M Sell
130,250
-39,014
-23% -$6.57M 0.15% 152
2021
Q4 		$43M Sell
169,264
-39,291
-19% -$11.5M 0.27% 92
2021
Q3 		$80.3M Sell
208,555
-98,459
-32% -$36.3M 0.55% 41
2021
Q2 		$72.1M Sell
307,014
-89,153
-23% -$15.9M 0.49% 44
2021
Q1 		$39.8M Hold
396,167
– – 0.33% 73
2020
Q4 		$41.4M Buy
+396,167
New +$40.1M 0.33% 73
2020
Q3 		– Sell
-285,834
Closed -$19.9M – 821
2020
Q2 		$18.6M Buy
+285,834
New +$15.7M 0.2% 130

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Beau Ventures
Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Lingotto Investment Management
Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return

Candriam SCA's MRNA Position: Q3 2026 in Review

Candriam SCA increased its Moderna (MRNA) stake by 24% in Q3 2026, buying an estimated $8.15M and bringing the position to 384,828 shares worth $74.4M. The position accounts for 0.33% of the portfolio, ranked #64.

Candriam SCA first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $80.3M in Q3 2021. 573 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Candriam SCA held 384,828 shares of Moderna worth $74.4M as of Q3 2026.
  • Candriam SCA bought 75,632 Moderna shares in Q3 2026, an estimated $8.15M.
  • Moderna made up 0.33% of Candriam SCA's portfolio in Q3 2026, its #64 holding.
  • Candriam SCA first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Candriam SCA's Moderna position peaked at $80.3M in Q3 2021.
  • 573 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.